Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Long-term follow-up reinforces PFS and OS benefit of lucicebtide plus standard of care in ndGBM: mPFS projected at 28.4 months, mOS not yet reached with 6 of 9 patients alive TARRYTOWN, N.Y., May 21, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company...